106.05
前日終値:
$104.25
開ける:
$105
24時間の取引高:
1.66M
Relative Volume:
1.09
時価総額:
$5.24B
収益:
$4.06B
当期純損益:
$413.08M
株価収益率:
13.24
EPS:
8.01
ネットキャッシュフロー:
$560.48M
1週間 パフォーマンス:
+6.10%
1か月 パフォーマンス:
-39.40%
6か月 パフォーマンス:
-46.38%
1年 パフォーマンス:
-53.91%
Charles River Laboratories International Inc Stock (CRL) Company Profile
名前
Charles River Laboratories International Inc
セクター
電話
781-222-6000
住所
251 BALLARDVALE ST, WILMINGTON, MA
CRL を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
CRL
Charles River Laboratories International Inc
|
106.05 | 5.24B | 4.06B | 413.08M | 560.48M | 8.01 |
![]()
TMO
Thermo Fisher Scientific Inc
|
427.50 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
![]()
DHR
Danaher Corp
|
186.83 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
![]()
IDXX
Idexx Laboratories Inc
|
411.49 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
![]()
A
Agilent Technologies Inc
|
102.48 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
![]()
IQV
Iqvia Holdings Inc
|
143.91 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-03-21 | ダウングレード | Goldman | Buy → Neutral |
2025-03-04 | アップグレード | Citigroup | Sell → Neutral |
2025-03-03 | アップグレード | Redburn Atlantic | Sell → Neutral |
2025-01-22 | ダウングレード | William Blair | Outperform → Mkt Perform |
2025-01-17 | ダウングレード | UBS | Buy → Neutral |
2024-11-18 | ダウングレード | CLSA | Hold → Underperform |
2024-11-07 | アップグレード | CLSA | Underperform → Hold |
2024-10-23 | 開始されました | CLSA | Underperform |
2024-10-14 | 開始されました | Redburn Atlantic | Sell |
2024-10-07 | ダウングレード | Evercore ISI | Outperform → In-line |
2024-10-02 | ダウングレード | BofA Securities | Buy → Neutral |
2024-10-01 | ダウングレード | Citigroup | Neutral → Sell |
2024-08-08 | ダウングレード | JP Morgan | Overweight → Neutral |
2024-08-08 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2024-06-28 | ダウングレード | Argus | Buy → Hold |
2024-06-07 | 開始されました | Mizuho | Neutral |
2024-06-06 | 開始されました | Goldman | Buy |
2024-02-15 | ダウングレード | Guggenheim | Buy → Neutral |
2023-09-13 | 開始されました | TD Cowen | Market Perform |
2023-07-10 | ダウングレード | Citigroup | Buy → Neutral |
2023-02-23 | アップグレード | Guggenheim | Neutral → Buy |
2023-01-12 | ダウングレード | Jefferies | Buy → Hold |
2022-09-30 | アップグレード | Jefferies | Hold → Buy |
2022-08-25 | 開始されました | Credit Suisse | Outperform |
2022-08-04 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2022-05-24 | 開始されました | Guggenheim | Neutral |
2022-04-25 | ダウングレード | Jefferies | Buy → Hold |
2022-04-07 | 開始されました | Stephens | Overweight |
2022-02-17 | 繰り返されました | BofA Securities | Buy |
2022-02-17 | アップグレード | Citigroup | Neutral → Buy |
2022-02-17 | 繰り返されました | Deutsche Bank | Buy |
2022-02-17 | 繰り返されました | Morgan Stanley | Overweight |
2022-02-17 | 繰り返されました | UBS | Buy |
2021-08-05 | 再開されました | Credit Suisse | Neutral |
2020-12-16 | ダウングレード | Citigroup | Buy → Neutral |
2020-09-10 | アップグレード | Jefferies | Hold → Buy |
2020-07-01 | アップグレード | BofA Securities | Neutral → Buy |
2020-05-13 | アップグレード | UBS | Neutral → Buy |
2020-04-21 | ダウングレード | Jefferies | Buy → Hold |
2020-03-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2020-03-02 | 開始されました | Deutsche Bank | Buy |
2020-02-18 | アップグレード | Wolfe Research | Peer Perform → Outperform |
2020-01-10 | アップグレード | Goldman | Neutral → Buy |
2020-01-08 | 開始されました | Wells Fargo | Overweight |
2020-01-07 | 開始されました | Citigroup | Buy |
2019-10-18 | ダウングレード | BofA/Merrill | Buy → Neutral |
2019-06-10 | 開始されました | SVB Leerink | Outperform |
2019-04-30 | 再開されました | Evercore ISI | Outperform |
2018-12-14 | 開始されました | Deutsche Bank | Buy |
2018-10-09 | 開始されました | UBS | Neutral |
2018-08-23 | アップグレード | Raymond James | Mkt Perform → Outperform |
2018-07-17 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
2018-06-15 | アップグレード | KeyBanc Capital Mkts | Sector Weight → Overweight |
2018-02-14 | アップグレード | SunTrust | Hold → Buy |
すべてを表示
Charles River Laboratories International Inc (CRL) 最新ニュース
According to the Latest Report: Dermatology CRO Market - openPR.com
Charles River Laboratories International, Inc. (CRL): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025 - MSN
20 Mid-Cap Stocks Insiders Were Buying in Q1 2025 - Insider Monkey
Ecotoxicology Market Detailed in New Research Report By 2032| Charles River Laboratories International - openPR.com
Baird Adjusts Price Target on Charles River Laboratories International to $118 From $101, Keeps Neutral Rating - marketscreener.com
Charles River (CRL) Receives Price Target Boost from Baird Analyst | CRL Stock News - GuruFocus
The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid? - Investing.com
The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid? - Benzinga
Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call | CRL Stock News - GuruFocus
Charles River Labs Earnings: Key Q1 2025 Results Coming May 7What to Watch - Stock Titan
Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength? - Yahoo
Charles River (CRL) Price Target Reduced Amid Challenges in Life Sciences Sector | CRL Stock News - GuruFocus
US Stocks Climb With Strong Performances From Real Estate And Utilities - Finimize
US Markets Climb As Sectors Shine With Solid Gains - Finimize
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN
TD Cowen Adjusts Charles River Laboratories International's PT to $105 From $179, Keeps Hold Rating - MarketScreener
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing - Benzinga
Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate - MSN
Charles River Gets Hit By The FDA, Too Early To Bet On A Comeback - Seeking Alpha
Charles River Faces Significant Regulatory And Macro Pressures (NYSE:CRL) - Seeking Alpha
Charles River (CRL) Faces Uncertainty with FDA's Shift from Animal Testing | CRL Stock News - GuruFocus
Wall Street Rebounds, JPMorgan Jumps On Strong Q1 Earnings: What's Driving Markets Friday? - Benzinga
Baird Adjusts PT on Charles River Laboratories International to $101 From $155, Keeps Neutral Rating - MarketScreener
Deutsche Bank Adjusts Price Target on Charles River Laboratories International to $140 From $210 - MarketScreener
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday? - Benzinga
Charles River (CRL) Faces Uncertainty with FDA's Shift on Animal Testing | CRL Stock News - GuruFocus
FDA's Shift in Testing Requirements Poses Challenge for Charles River (CRL) | CRL Stock News - GuruFocus
Why Charles River Laboratories International, Inc. (CRL) Went Down On Thursday? - Insider Monkey
Charles River Labs Stock (CRL) Crashes 28% as FDA Signals End of Animal Testing Era - TipRanks
Charles River: Putting FVE Under Review After FDA Announces Plans to Phase Out Animal Testing - Morningstar
Charles River Laboratories (CRL) Faces Impact from FDA's Shift A - GuruFocus
Inotiv and Charles River stock tumble as FDA moves away from animal testing - Investing.com Canada
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Charles River Labs stock tumbles as FDA shifts from animal testing - Investing.com Canada
FDA Shifts Away from Animal Testing, Charles River (CRL) Shares Could Be Impacted | CRL Stock News - GuruFocus
FDA to phase out animal testing requirement, adopt AI methods - Seeking Alpha
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MSN
Barclays Adjusts Price Target for Charles River (CRL) Ahead of Q - GuruFocus
Barclays Sticks to Their Hold Rating for Charles River Labs (CRL) - The Globe and Mail
ROSEN, LEADING INVESTOR COUNSEL, Encourages Charles River Laboratories International, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class ActionCRL - MarketScreener
Charles River Stock: A Deep Dive Into Analyst Perspectives (11 Ratings) - Benzinga
Evercore ISI Adjusts PT on Charles River Laboratories International to $135 From $175, Maintains In Line Rating - MarketScreener
With new site in hand, Portuguese biotech stakes out Peninsula plans - The Business Journals
Revenues Working Against Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Following 30% Dive - simplywall.st
Goldman Sachs Adjusts Charles River Laboratories International PT to $150 From $170, Maintains Neutral Rating - MarketScreener
Charles River Labs stock hits 52-week low at $132.57 - Investing.com Australia
Bioburden Testing Market Demand, Growth and Future Scope - openPR.com
Charles River Labs stock hits 52-week low at $132.57 By Investing.com - Investing.com UK
Animal Model Market Generated Opportunities, Future Scope 2025-2032 | Charles River Laboratories International - openPR.com
Cell Banking Outsourcing Market Deep Research 2025-2032 | Charles River Laboratories, Cryo-Cell International Inc - openPR.com
Charles River Laboratories International Inc (CRL) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):